Smoking and lung cancer
cigarette smoking; lung cancer; gene polymorphism; risk of lung cancer; screening
Smoking and lung cancer
Invited review paper
Pneumonol Alergol Pol 2009;77(5):469-473.
risk of lung cancer
- Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. CA: A Cancer Journal for Clinicians. 2007; 57(1): 43–66.
- Didkowska J, Manczuk M, McNeill A, et al. Lung cancer mortality at ages 35-54 in the European Union: ecological study of evolving tobacco epidemics. BMJ. 2005; 331(7510): 189–191.
- Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J. 1976; 2(6051): 1525–1536.
- Higgins IT. Epidemiology of lung cancer in the United States. IARC Sci Publ. 1977; 16: 191–203.
- Little JB, Kennedy AR, McGandy RB. Lung cancer induced in hamsters by low doses of alpha radiation from polonium-210. Science. 1975; 188(4189): 737–738.
- Kushinsky R, Louis CJ. The effect of cigarette smoke on aryl hydrocarbon hydroxylase activity and cytochrome P450 content in rat liver and lung microsomes. Oncology. 1976; 33(5-6): 197–200.
- West R, Zatonski W, Przewozniak K, et al. Can we trust national smoking prevalence figures? Discrepancies between biochemically assessed and self-reported smoking rates in three countries. Cancer Epidemiol Biomarkers Prev. 2007; 16(4): 820–822.
- Gray N, Boyle P, Zatonski W. Tar concentrations in cigarettes and carcinogen content. Lancet. 1998; 352(9130): 787–788.
- Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003; 3(10): 733–744.
- Wogan GN, Hecht SS, Felton JS, et al. Environmental and chemical carcinogenesis. Semin Cancer Biol. 2004; 14(6): 473–486.
- Dennisenko MF, Pao A, Tang M, et al. Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hot spots on P53. Science. 1996; 274: 430–432.
- Hirsch F, Fischer J, Niklinski J, et al. Future developments in the treatment of lung cancer. Lung Cancer. 2002; 38: 81–85.
- Jassem J, Jassem E, Jakóbkiewicz-Banecka J, et al. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Cancer. 2004; 100(9): 1951–1960.
- Agapitos E, Mollo F, Tomatis L, et al. Epithelial, possibly precancerous, lesions of the lung in relation to smoking, passive smoking, and socio-demographic variables. Scand J Soc Med. 1996; 24(4): 259–263.
- Wistuba II, Behrens C, Milchgrub S, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 1999; 18(3): 643–650.
- Ogiwara H, Kohno T, Nakanishi H, et al. Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer. Oncogene. 2008; 27(35): 4788–4797.
- Soria JC, Xu X, Liu DD, et al. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst. 2003; 95(2): 165–168.
- Capkova L, Kalinova M, Krskova L, et al. Loss of heterozygosity and human telomerase reverse transcriptase (hTERT) expression in bronchial mucosa of heavy smokers. Cancer. 2007; 109(11): 2299–2307.
- Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol. 1998; 16(3): 1207–1217.
- Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54(18): 4855–4878.
- Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001; 92(6): 1525–1530.
- Blons H, Pallier K, Le Corre D, et al. Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC Med Genomics. 2008; 1: 25–38.
- Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998; 95(20): 11891–11896.
- Zöchbauer-Müller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001; 61(1): 249–255.
- Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002; 62(8): 2370–2377.
- Brena RM, Morrison C, Liyanarachchi S, et al. Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Med. 2007; 4(3): e108.
- West K, Linnoila I, Brognard J, et al. Tobacco Carcinogen-Induced Cellular Transformation Increases Akt Activation In Vitro and In Vivo. Chest. 2004; 125(5): 101–102.
- Hope BT, Nagarkar D, Leonard S, et al. Long-term upregulation of protein kinase A and adenylate cyclase levels in human smokers. J Neurosci. 2007; 27(8): 1964–1972.
- Szymanowska A, Jassem E, Skrzypski M, et al. Gene expression profiles In woman with lung adenocarcinoma according to cigarette smoking history. JTO. 2008(supl. 6): A 777.
- Powell CA, Spira A, Derti A, et al. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol. 2003; 29(2): 157–162.
- Lubin JH, Caporaso NE. Cigarette smoking and lung cancer: modeling total exposure and intensity. Cancer Epidemiol Biomarkers Prev. 2006; 15(3): 517–523.
- Sieminska A, Buczkowski K, Jassem E, et al. Lack of association between serotonin transporter gene polymorphism 5-HTTLPR and smoking among Polish population: a case-control study. BMC Med Genet. 2008; 9: 76–84.
- Szymanowska A, Jassem E, Dziadziuszko R, et al. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer. 2006; 52(1): 9–14.
- Guo Y, Zhang X, Yang M, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006; 27(1): 110–117.
- Jassem J, Szymanowska A, Jassem E, et al. Arg72Pro P53 gene polymorphism: Clinical relevance and relation with P53 mutations in non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 2004; 22(14_suppl): 7158–7158.
- Lu C, Spitz MR, Zhao H, et al. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006; 106(2): 441–447.
- Skuladottir H, Autrup H, Autrup J, et al. Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway. Lung Cancer. 2005; 48(2): 187–199.
- Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14(2): 491–496.
- Drozdowska A, Szymanowska A, Jassem E, et al. P2-011: Occurrence and clinical significance of hOGG1 Ser326Cys polymorphism in NSCLC patients from Northern Poland. Journal of Thoracic Oncology. 2007; 2(8): S486.
- Wu X, Zhao H, Wei Q, et al. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis. 2003; 24(3): 505–509.
- Zienolddiny S, Campa D, Lind H, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Mutat Res. 2004; 546: 65.
- Rudd MF, Webb EL, Matakidou A, et al. GELCAPS Consortium. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res. 2006; 16(6): 693–701.
- Wong LS, Green HM, Feugate JoE, et al. Effects of "second-hand" smoke on structure and function of fibroblasts, cells that are critical for tissue repair and remodeling. BMC Cell Biol. 2004; 5: 13.
- Nyberg F, Agudo A, Boffetta P, et al. A European validation study of smoking and environmental tobacco smoke exposure in nonsmoking lung cancer cases and controls. Cancer Causes Control. 1998; 9(2): 173–182.
- Kirkland L. Environmental Tobacco Smoke and Lung Cancer in Nonsmoking Women. JAMA: The Journal of the American Medical Association. 1995; 273(7): 519–520.
- Divine KK, Pulling LC, Marron-Terada PG, et al. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer. 2005; 114(3): 400–405.
- Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst. 1993; 85(6): 457–464.
- Sobue T, Suzuki T, Fujimoto I, et al. Lung cancer risk among exsmokers. Jpn J Cancer Res. 1991; 82(3): 273–279.
- Lee IM, Cok NR, Zaziano JM, et al. Vitamin E in the primary prevention of cardiovascular and cancer: the Women’s Heath Study; a randomized controlled trial. JAMA. 2005; 294: 56–65.
- Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996; 334(18): 1150–1155.
- van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst. 2000; 92(12): 977–986.
- Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988; 296(6618): 313–316.
- Pendyala L, Schwartz G, Bolanowska-Higdon W, et al. Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity. Cancer Epidemiol Biomarkers Prev. 2001; 10(3): 269–272.
- Bach PB, Kelley MJ, Tate RC, et al. Screening for lung cancer: a review of the current literature. Chest. 2003; 123(1 Suppl): 72S–82S.
- Hunt I, Siva M, Southon R, et al. Does lung cancer screening with low-dose computerised tomography (LDCT) improve disease-free survival? Interact Cardiovasc Thorac Surg. 2006; 5(5): 612–615.
- Black C, Bagust A, Boland A, et al. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess. 2006; 10(3): 1–90.
- Zhong Li, Hidalgo GE, Stromberg AJ, et al. Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med. 2005; 172(10): 1308–1314.
- Machado RF, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med. 2005; 171(11): 1286–1291.
- McRonald FE, Yadegarfar G, Baldwin DR, et al. The Liverpool Lung Project: a molecular epidemiological study of early lung cancer detection. Eur Respir J. 2002; 20(2): 464–479.
- Friedman GD, Flick ED, Udaltsova N, et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008; 17(1): 27–36.
- Jassem J. Nowotwory płuc i opłucnej. In: Szczeklik A. ed. Choroby wewnętrzne. Medycyna Praktyczna, Kraków 2005: 603–615.
- Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med. 1993; 119(5): 383–390.
- Gritz ER, Nisenbaum R, Elashoff RE, et al. Smoking behavior following diagnosis in patients with stage I non-small cell lung cancer. Cancer Causes Control. 1991; 2(2): 105–112.